For long term debt instruments
Ranbaxy Laboratories has announced that Credit Analysis & Research (CARE), has revised credit rating for long term debt instruments issued by the Company, from CARE AA+ (DoubIe A Plus) to CARE AA (Double A). Long term instruments with CARE AA rating are considered to have high degree of safety regarding timely payment of financial obligations and carry very low credit risk.However, CARE has reaffirmed the CARE A1+(A One Plus) rating assigned to the short term bank facilities of the Company. Short term debt instruments with CARE rating of A1+ are considered to have very strong degree of safety regarding timely payment of financial obligations and carry lowest credit risk.
Powered by Capital Market - Live News
